EYPT
Eyepoint Pharmaceuticals Inc
3.30$
-4.4%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.7% | -16.7% | -18.9% | +11.0% | +10.1% | +111.0% | -78.2% | -81.9% | -35.8% | +12.3% | -27.2% | – | |
| – | -17.0% | -23.9% | +84.6% | -47.5% | +10.9% | -1.3% | -79.5% | +337.0% | -48.0% | +40.8% | -100.0% | – | |
| – | -6.9% | -16.2% | -26.1% | +21.2% | +10.1% | +119.5% | -78.1% | -95.3% | +0.0% | -31.4% | +201.8% | – | |
| – | +3.4% | +67.9% | -1.1% | -0.9% | +46.8% | +35.1% | -5.3% | -14.0% | +24.0% | +21.8% | +15.9% | – | |
| – | +6.6% | +25.4% | -9.6% | +1.7% | -2.9% | +10.2% | -14.5% | +22.2% | -21.4% | +33.9% | -6.6% | – | |
| – | +3.5% | +50.6% | -3.7% | -0.2% | +31.7% | +29.4% | -7.0% | -7.6% | +13.4% | +23.8% | +12.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -95.5% | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.